Article
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
Blood - 8 Nov 2012
Xu-Monette Zijun Y, Wu Lin, Visco Carlo, Tai Yu Chuan, Tzankov Alexander, Liu Wei-min, Montes-Moreno Santiago, Dybkaer Karen, Chiu April, Orazi Attilio, Zu Youli, Bhagat Govind, Richards Kristy L, Hsi Eric D, Zhao X Frank, Choi William W L, Zhao Xiaoying, van Krieken J Han, Huang Qin, Huh Jooryung, Ai Weiyun, Ponzoni Maurilio, Ferreri Andrés J M, Zhou Fan, Kahl Brad S, Winter Jane N, Xu Wei, Li Jianyong, Go Ronald S, Li Yong, Piris Miguel A, Møller Michael B, Miranda Roberto N, Abruzzo Lynne V, Medeiros L Jeffrey, Young Ken H
Abstract excerpt
TP53 mutation is an independent marker of poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (CHOP) therapy. However, its prognostic value in the rituximab immunochemotherapy era remains undefined. In the present study of a large cohort of DLBCL patients treated with rituximab plus CHOP (R-CHOP), we show that those...
Topics
- Adult
- Aged
- Alleles
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols
- Cohort Studies